

# Prof. Dr. med. Georg Lenz, MD

Current Position: Director of Department of Internal Medicine A, University Hospital Münster  
Contact: Department of Internal Medicine A  
Hematology, Haemostaseology, Oncology and Pneumology,  
Albert-Schweitzer-Campus 1, Building A1  
48149 Münster, Germany  
Ph: +49 251 83 47587, Fax: +49 251 83 47588  
E-mail: [georg.lenz@ukmuenster.de](mailto:georg.lenz@ukmuenster.de)

## EDUCATION

1994-2001 School of Medicine at the Universität Erlangen-Nürnberg and at the Freie Universität of Berlin.

## PROFESSIONAL EXPERIENCE

01/2002-01/2005 Assistant physician at the Department of Internal Medicine III Hematology/Oncology at the Klinikum Grosshadern at the Ludwig-Maximilians Universität, Munich.

01/2005-03/2009 Postdoctoral research fellow in the Laboratory of Dr. Louis Staudt at the Lymphoid Malignancies Section, Metabolism Branch at the National Cancer Institute, Bethesda, USA.

03/2009-09/2014 Principal investigator at the Department of Hematology, Oncology and Tumor Immunology at the Charité – Universitätsmedizin Berlin.

11/2009 Appointment as Assistant professor on the “Molecular Pathogenesis of malignant Lymphomas” at the Charité – Universitätsmedizin Berlin.

10/2012-09/2013 Senior physician in the Department of Hematology, Oncology and Tumor Immunology at the Charité – Universitätsmedizin Berlin.

09/2013-09/2014 Senior leading physician in the Department of Hematology, Oncology and Tumor Immunology at the Charité – Universitätsmedizin Berlin.

10/2014-07/2017 W3 Professorship and Head of the “Translational Oncology Unit”, University Hospital Münster.

Since 08/2017 Director of Department of Internal Medicine A, University Hospital Münster.

## BOARD CERTIFICATION

Board certified in Internal Medicine  
Board certified in Hematology and Oncology

## CLINICAL TRIALS EXPERIENCE

Numerous studies performed as principal investigator. Country and global lead of various clinical trials in Hematology.

## EXPERIENCE IN CLINICAL TRIAL STUDY GROUPS

Since 2017: Chair of the German Aggressive lymphoma study Group within the German Lymphoma Alliance (GLA)  
Since 2017: Steering committee member of the German Lymphoma Alliance (GLA)  
Since 2015: Member of the „Scientific Advisory Board“ of the German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)  
2016-2017: Speaker of the Early Trials Network study group

## AWARDS

08/2008 Technology Transfer Award of the National Cancer Institute  
10/2009 World Health Summit & Pfizer Award

10/2013 Artur-Pappenheim Award of the German Society of Hematology and Oncology  
11/2013 Together with Daniel Krappmann and colleagues: Paula und Richard von Hertwig-Preis für interdisziplinäre Zusammenarbeit, Helmholtz Zentrum Munich  
11/2013 Monika Kutzner Award for Cancer Research

## REVIEWER

Reviewer for major hematologic and oncologic scientific journals (e.g. Nature Medicine, Nature communications, Cell reports, JCI, JCO, Blood, etc.) and scientific organizations (e.g. different funding organizations, ASH, EHA, various universities, etc.)

## MEMBERSHIP

Active member of the American Society of Hematology (ASH)  
Active member of the European Hematology Association (EHA)  
Active member of the German Society of Hematology and Oncology (DGHO)

## SELECTED PUBLICATIONS:

1. Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, **Lenz G**. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. *Blood*. 2017 Jul 20; 130 (3): 310-322.
2. Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, **Lenz G**. B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. *Blood*. 2017 Jan 19; 129 (3): 333-346.
3. Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dörken B, Chu YW, Chen AI, Lebovic D, Salles GA, Czuczman MS, Palanca-Wessels MC, Press OW, Advani R, Morschhauser F, Cheson BD, Lenz P, Ott G, Polson AG, Mundt KE, **Lenz G**. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. *Leukemia* 2015 Jul; 29 (7): 1578-86.
4. Weilemann A., Grau M., Erdmann T., Merkel O., Sobhifshar U., Anagnostopoulos I., Hummel M., Siegert A., Hayford C., Madle H., Wollert-Wulf B., Fichtner I., Dörken B., Dirnhofer S., Mathas S., Janz M., Emre NC., Rosenwald A., Ott G., Lenz P., Tzankov A., **Lenz G**. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. *Blood*. 2015 Jan 1; 125 (1): 124-32.
5. Rahal R., Frick M., Romero R., Korn JM., Kridel R., Chunchan F., Meissner B., Bhang H., Ruddy D., Kauffmann A., Farsidjani A., Derti A., Rakiec D., Naylor T., Pfister E., Kovats S., Kim S., Dietze K., Dörken B., Steidl C., Tzankov A., Hummel M., Monahan J., Morrissey M., Fritsch C., Sellers WR., Cooke VG., Gascoyne RD., **Lenz G**\*, Stegmeier F\*. Pharmacological and genomic profiling identifies NFκB-targeted treatment strategies for mantle cell lymphoma. *Nature Medicine*. 2014 Jan; 20 (1): 87-92. **\*Equally contributing last and corresponding author.**
6. Nogai H., Wenzel SS., Hailfinger S., Grau M., Kaergel E., Seitz V., Wollert-Wulf B., Pfeifer M., Wolf A., Frick M., Dietze K., Madle H., Tzankov A., Hummel M., Dörken B., Scheidereit C., Janz M., Lenz P., Thome M., **Lenz G**. IκB-z controls the constitutive NF-κB target gene network and survival of ABC DLBCL. *Blood*. 2013 Sep 26; 122 (13): 2242-50.
7. Pfeifer M., Grau M., Lenze D., Wenzel SS., Wolf A., Wollert-Wulf B., Dietze K., Nogai H., Storek B., Madle H., Dörken B., Janz M., Dirnhofer S., Lenz P., Hummel M., Tzankov A., **Lenz G**. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. *PNAS*. 2013 Jul 23; 110 (30): 12420-5.

8. Davis RE\*, Ngo VN\*, **Lenz G\***, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Brazier RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. *Nature*. 2010 Jan 7; 463 (7277): 88-92. **\*Equally contributing first author.**
9. **Lenz G**, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Brazier RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM. Stromal gene signatures in large-B-cell lymphomas. *N Engl J Med*. 2008 Nov 27; 359 (22): 2313-23.
10. **Lenz G\***, Davis RE\*, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. *Science*. 2008 Mar 21; 319 (5870): 1676-9. **\*Equally contributing first author.**